Description
MODIFICATION P00011 IS ISSUED TO INCORPORATE SANDOZ INC 2026 SUBCONTRACTING PLAN EFFECTIVE 01/01/2026 -12/31/2026.
Base award description: NEW AWARD FOR AMOXICILLIN_CLAVULANATE TABLETS WITH SANDOZ, INC. ORDERING PERIOD IS JAN 15, 2023 TO JAN 14, 2024 WITH FOUR ONE-YEAR OPTIONS.
Modification chain · 12 transactions
Each row is one published transaction. This action is the obligation recorded on that transaction — a change amount, as USAspending publishes it. Running total is computed by Glassbox VA as the cumulative sum of those amounts up to and including the row, so the last running total equals the award's net obligations shown above. The cumulative-total columns in the source files are not used: they are not frozen per modification.
- Base2022-10-13+$0= $0
- Mod P000012022-10-21+$0= $0
- Mod P000022022-12-21+$0= $0
- Mod P000032023-04-24+$0= $0
- Mod P000042023-12-07+$0= $0
- Mod P000052024-02-01+$0= $0
- Mod P000062024-02-14+$0= $0
- Mod P000072024-02-15+$0= $0
- Mod P000082024-12-10+$0= $0
- Mod P000092024-12-30+$0= $0
- Mod P000102025-12-16+$0= $0
- Mod P000112026-01-08+$0= $0
| Transaction | Action date | This action (delta) | Running total | Description on this transaction |
|---|---|---|---|---|
| Base | 2022-10-13 | +$0 | $0 | NEW AWARD FOR AMOXICILLIN_CLAVULANATE TABLETS WITH SANDOZ, INC. ORDERING PERIOD IS JAN 15, 2023 TO JAN 14, 202… |
| Mod P00001· SUPPLEMENTAL AGREEMENT FOR WORK WITHIN SCOPE | 2022-10-21 | +$0 | $0 | NDC CHANGES ON TWO AMOXICILLIN_CLAVULANATE TABLET NDCS. OLD NDCS WILL BE REMOVED FROM CONTRACT. |
| Mod P00002· ADD SUBCONTRACTING PLAN | 2022-12-21 | +$0 | $0 | INCORPORATE 2023 SANDOZ SUBCONTRACTING PLAN FOR AMOXICILLIN_CLAVULANATE TABLETS WITH EFFECTIVE 01/01/2023 THRO… |
| Mod P00003· OTHER ADMINISTRATIVE ACTION | 2023-04-24 | +$0 | $0 | INCORPORATION OF DRUG SUPPLY CHAIN SECURITY ACT (DSCSA) LANGUAGE |
| Mod P00004· EXERCISE AN OPTION | 2023-12-07 | +$0 | $0 | EXERCISE OPTION YEAR 1 EFFECTIVE JANUARY 15, 2024 THROUGH JANUARY 14, 2025 FOR AMOXICILLIN/CLAVULANATE TABLETS… |
| Mod P00005· ADD SUBCONTRACTING PLAN | 2024-02-01 | +$0 | $0 | INCORPORATE 2024 SANDOZ SUBCONTRACTING PLAN FOR AMOXICILLIN_CLAVULANATE TABLETS WITH EFFECTIVE 01/01/2024 THRO… |
| Mod P00006· SUPPLEMENTAL AGREEMENT FOR WORK WITHIN SCOPE | 2024-02-14 | +$0 | $0 | UPDATE TO COST RECOVERY FEE (CRF) AND SUBMISSION OF QUARTERLY SALES REPORTS FOR 36E79723D0001 SANDOZ INC. AMOX… |
| Mod P00007· OTHER ADMINISTRATIVE ACTION | 2024-02-15 | +$0 | $0 | POC ADMINISTRATIVE CHANGE |
| Mod P00008· EXERCISE AN OPTION | 2024-12-10 | +$0 | $0 | EXERCISE OPTION YEAR 2 WITH NO PRICE CHANGES |
| Mod P00009· ADD SUBCONTRACTING PLAN | 2024-12-30 | +$0 | $0 | 2025 SUBK SMALL BUSINESS SUBCONTRACTING PLAN |
| Mod P00010· EXERCISE AN OPTION | 2025-12-16 | +$0 | $0 | EXERCISE OPTION YEAR 3 EFFECTIVE JAN 15, 2026 TO JAN 14, 2027 FOR AMOXICILLIN/CLAVULANATE TABLETS WITH SANDOZ. |
| Mod P00011· ADD SUBCONTRACTING PLAN | 2026-01-08 | +$0 | $0 | MODIFICATION P00011 IS ISSUED TO INCORPORATE SANDOZ INC 2026 SUBCONTRACTING PLAN EFFECTIVE 01/01/2026 -12/31/2… |
Related awards · 11
Awards are related by an explicit link in the data, stated for each group below — never by text similarity. Values are net obligations.
Other VA awards to the same recipient (UEI ETJGHMFH1MT5)
| Award | Office · PSC / listing | Net obligations | FY |
|---|---|---|---|
| 36F79723D0187 | NAC FEDERAL SUPPLY SCHEDULE (36F797) · 6505 · DRUGS AND BIOLOGICALS | $0 | FY2023 |
| 36E79723D0005 | NAC PHARMACEUTICALS (36E797) · 6505 · DRUGS AND BIOLOGICALS | $0 | FY2023 |
| 36E79722D0033 | NAC PHARMACEUTICALS (36E797) · 6505 · DRUGS AND BIOLOGICALS | $0 | FY2022 |
| 36E79722D0016 | NAC PHARMACEUTICALS (36E797) · 6505 · DRUGS AND BIOLOGICALS | $0 | FY2022 |
| 36E79722D0011 | NAC PHARMACEUTICALS (36E797) · 6505 · DRUGS AND BIOLOGICALS | $0 | FY2022 |
| 36E79721D0010 | NAC PHARMACEUTICALS (36E797) · 6505 · DRUGS AND BIOLOGICALS | $0 | FY2021 |
Other recipients under 6505 from NAC PHARMACEUTICALS (36E797) (most recent first)
| Award | Recipient | Office | Net obligations | FY |
|---|---|---|---|---|
| 36E79726A0025 | CHIESI USA INC | NAC PHARMACEUTICALS (36E797) | $0 | FY2026 |
| 36E79726A0024 | NEUROTECH PHARMACEUTICALS, INC | NAC PHARMACEUTICALS (36E797) | $0 | FY2026 |
| 36E79726A0023 | TAKEDA PHARMACEUTICALS AMERICA, INC. | NAC PHARMACEUTICALS (36E797) | $0 | FY2026 |
| 36E79726D0041 | GOLDEN STATE MEDICAL SUPPLY, INC. | NAC PHARMACEUTICALS (36E797) | $0 | FY2026 |
| 36E79726A0022 | AURINIA PHARMA US INC | NAC PHARMACEUTICALS (36E797) | $0 | FY2026 |
Cite as: Glassbox VA record view · VA contract (USAspending / FPDS) · CONT_IDV_36E79723D0001_3600 · retrieved 2026-09-26.